Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 16, 2011

Platypus Licenses Cell Exclusion Zone Technology to Cell Biolabs

  • Platypus Technologies signed an agreement granting Cell Biolabs a license to use its cell exclusion zone technology. The deal allows Cell Biolabs to incorporate the technology into its CytoSelect™ cell-migration assays.

    “There is a growing demand for cell motility assays that allow visual assessment of cell morphology,” says Renee Herber, program manager at Platypus. “This partnership should allow us to service a greater number of researchers for whom more data per assay well is critical.”

    Cell Biolabs develops and commercializes assays and reagents to advance cell and molecular biology. Platypus’ Oris™ cell-based assay line is designed to aid life science researchers studying cell migration and cell invasion.

    Last October, the company launched the latest product in the Oris line, the Oris™ Pro 384 Cell Migration Assay. It is reportedly designed for high-throughput screening of chemical libraries for cancer therapeutics. The assay was developed using a $396,000 Innovative Molecular Analysis Technologies grant from the NCI.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »